Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation

Priestman, T. J.; Roberts, J.T.; Lucraft, H. H.; Collis, C.; Adams, Malcolm; Upadhyaya, B. K.; Priestman, S.

doi:10.1016/s0936-6555(05)80790-3

Cited by 89 publications

(34 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The low utilisation of 5-HT 3 antagonists is not in line with evidence-based suggestions for this patient group, both in older [19,21,35] and in more recently updated antiemetic guidelines based on randomised controlled studies [17,27,31]. During upper abdominal irradiation, it has been shown that a 5-HT 3 antagonist given prophylactic (43% had nausea) was more effective than placebo (58% had nausea) [28] and was more effective than corticosteroids only [40]. A combined treatment with a 5-HT 3 antagonist and corticosteroids given as prophylaxis had additional effects compared to a 5-HT 3 antagonist combined with placebo (77% versus 88% experienced nausea or vomiting) [37].…”

Section: Discussionmentioning

confidence: 99%

One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient

Enblom

Axelsson

Steineck

et al. 2008

Support Care Cancer

View full text Add to dashboard Cite

Objective To describe the prevalence of nausea and vomiting during radiotherapy and to compare quality of life, psychological and functional status in patients experiencing or not experiencing nausea.Materials and methods A cross-sectional selection of 368 cancer patients treated with radiotherapy answered a questionnaire (=93% answering rate) regarding nausea, vomiting, actual use of and interest in antiemetic treatment, quality of life and psychological and functional status during the preceding week of radiotherapy. Mean age was 60 years and 66% were women. Main results Nausea was experienced by 39% (145) and vomiting by 7% (28) of patients in general, by 63% in abdominal or pelvic fields and by 48% in head/neck/brain fields. Abdominal/pelvic field (Relative risk (RR) 2.0), age ≤40 years (RR 1.9) and previous nausea in other situations (RR 1.8) implied an increased risk for nausea. Antiemetics were used by 17% and 78% were interested in or wanted more information about acupuncture treatment against nausea. Of the 145 nauseous patients only 25% felt that antiemetics had helped them and 34% would have liked additional treatment, although the nausea intensity was mild in 72%. The nauseous patients reported lower well-being and quality of life, lower satisfaction with aspects of daily living and more frequent anxiety and depressed mood than the patients without nausea. Conclusions Of all patients undergoing radiotherapy, 39% experienced nausea and one third of them would have liked more treatment against the nausea. This study stresses the importance to identify and adequately treat patients with increased risk for nausea related to radiotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient

Enblom

Axelsson

Steineck

et al. 2008

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…HBI provides high rates of response (63-96%) with a fast onset of pain relief (1-3 days) [Salazar et al 1978[Salazar et al , 1986[Salazar et al , 1996[Salazar et al , 2001Hoskin et al 1989;Zelefsky et al 1989;Dearnaley et al 1992;Poulter et al 1992;Bashir et al 2008; [Salazar et al 1978] and pneumonitis characterized by cough, dyspnea and characteristic radiographic changes [Van Dyk et al 1981;Fryer et al 1978]. Radiation dose reduction, lung shielding and management of toxicity with glucocorticoids, antinauseants and intravenous hydration have improved these complications [Salazar et al 1978;Priestman et al 1990;Bashir et al 2008;Berg et al 2009]. …”

Section: Hemibody Irradiationmentioning

confidence: 99%

The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer

Rose

Crook

2015

Therapeutic Advances in Urology

View full text Add to dashboard Cite

show abstract

“…Ondansetron has been widely used in anticancer chemotherapy with better results than metoclopramide in controlling nausea and vomiting (6). It is also effective after radiotherapy (7), even in children and elderly people with low tolerance to metoclopramide.…”

Section: Original Articlementioning

confidence: 99%

Antiemetic Effects of Lerisetron in Radiation-induced Emesis in the Dog

Segura¹,

Grande²,

Miguel³

1998

Acta Oncologica

View full text Add to dashboard Cite

Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation

Cited by 89 publications

References 7 publications

One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient

One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient

The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer

Antiemetic Effects of Lerisetron in Radiation-induced Emesis in the Dog

Contact Info

Product

Resources

About